<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lack of immunogenicity of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells has been considered a major reason for their failure in induction of a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specific T cell response </plain></SENT>
<SENT sid="1" pm="."><plain>In this paper, we present evidence that <z:chebi fb="0" ids="50131">decitabine</z:chebi> (DAC), a DNA methylation inhibitor that is currently used for the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and other malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, is capable of eliciting an anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cytotoxic T lymphocyte (CTL) response in mouse EL4 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> model </plain></SENT>
<SENT sid="2" pm="."><plain>C57BL/6 mice with established EL4 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were treated with DAC (1.0 mg/kg body weight) once daily for 5 days </plain></SENT>
<SENT sid="3" pm="."><plain>We found that DAC treatment resulted in infiltration of IFN-Î³ producing T lymphocytes into <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and caused <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> rejection </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_63'>Depletion</z:mpath> of CD8(+), but not CD4(+) T cells resumed <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>DAC-induced CTL response appeared to be elicited by the induction of CD80 expression on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain>Epigenetic evidence suggests that DAC induces CD80 expression in EL4 cells via demethylation of CpG <z:chebi fb="0" ids="47885">dinucleotide</z:chebi> sites in the promoter of CD80 gene </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, we also showed that a transient, low-dose DAC treatment can induce CD80 gene expression in a variety of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>This study provides the first evidence that epigenetic modulation can induce the expression of a major T cell co-stimulatory molecule on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, which can overcome immune tolerance, and induce an efficient anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> CTL response </plain></SENT>
<SENT sid="9" pm="."><plain>The results have important implications in designing DAC-based <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> immunotherapy </plain></SENT>
</text></document>